Cephalalgia最新文献

{"title":"App-based self-administered biofeedback for the prevention of episodic migraine: A randomized controlled trial.","authors":"Amalie Christine Poole, Anker Stubberud, Melanie Rae Simpson, Lise Rystad Øie, Erling Tronvik, Espen Saxhaug Kristoffersen, Marte-Helene Bjørk, Iben Cornelia Keim Larsen, Kjersti Grøtta Vetvik, Nina Bäcklund, Joakim Høgsteggen Østhus, Joan Crespi, Oda Vardenær Lunder, Andrej Netland Khanevski, Ane Bakke Øvrevik, Alexander Olsen, Mattias Linde, Øyvind Salvesen, Tore Wergeland","doi":"10.1177/03331024261480724","DOIUrl":"10.1177/03331024261480724","url":null,"abstract":"<p><p>AimTo evaluate the efficacy and safety of a fully self-administered, app-based biofeedback intervention for the prevention of episodic migraineMethodsThis open-label, randomized, waitlist-controlled multicenter trial included adults with episodic migraine assigned to 12 weeks of daily biofeedback or a waitlist control. The primary outcome was change in monthly migraine days (MMDs) from baseline to weeks 9-12. Secondary outcomes included migraine intensity, acute medication use, and migraine-specific quality of life (MSQ v2.1). Statistical analyses were performed according to the intention-to-treat principle by a statistician masked to treatment assignment.ResultsOf 1113 individuals screened, 279 participants (mean [SD] age, 41 [10] years; 92% women) were randomized to the intervention (n = 140) or waitlist control (n = 139). Baseline MMDs were 4.8 (2.4) and 4.6 (2.3) in the intervention and control groups, respectively. During weeks 9-12, the estimated reduction in MMDs was 0.9 days (95% CI, -1.4 to -0.5) in the intervention group and 0.0 days (95% CI, -0.5 to 0.4) in the control group (between-group difference, 0.9 days; 95% CI, 0.3 to 1.5; P = 0.002). Participants receiving biofeedback also showed greater improvements in MSQ v2.1 total scores (mean difference, 5.3 points; 95% CI, 2.1 to 8.6; P = 0.001). Nine device-related adverse events occurred, all with mild severity.ConclusionApp-based self-administered biofeedback was associated with a statistically significant reduction in migraine frequency and improved quality of life, with a favorable safety profile.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 9","pages":"3331024261480724"},"PeriodicalIF":5.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered integration of bodily and visual signals in visual snow syndrome.","authors":"Sophie De Beukelaer, Insa Schlossmacher, Sarah A Aeschlimann, Antonia Klein, Andreas Szukics, Matthias Ertl, Christoph J Schankin","doi":"10.1177/03331024261480300","DOIUrl":"https://doi.org/10.1177/03331024261480300","url":null,"abstract":"<p><p>BackgroundVisual snow syndrome (VSS) is characterized by persistent visual disturbances and is considered to involve altered sensory integration and salience processing. Neuroimaging studies suggest aberrant attention and salience network integration, yet the real-time interaction between internal bodily signals and external sensory processing remains unclear.MethodsWe conducted a case-control electroencephalogram study in 18 VSS patients and 16 matched controls performing a visual oddball task with standard and deviant stimuli. Heartbeat-evoked potentials (HEP) were extracted as an index of cortical interoceptive processing and visual mismatch negativity (MMN) as a marker of exteroceptive prediction error. Trial-wise analyses and source localization assessed interoceptive-exteroceptive interactions.ResultsVSS participants exhibited altered HEP amplitudes relative to controls, together with reduced condition-dependent differentiation between standard and deviant trials. The relationship between HEP and MMN amplitudes was significantly moderated by group and associated with symptom intensity in VSS. Source analysis localized these effects to a left frontotemporal network.ConclusionsVSS is associated with altered interoceptive-exteroceptive interactions during visual perception, which may contribute to persistent visual symptoms.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 9","pages":"3331024261480300"},"PeriodicalIF":5.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148879312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EMHA migraine scoring system: A novel, valid, and reliable metric to capture severity, align with patients, and facilitate communication.","authors":"Patricia Pozo-Rosich, Edoardo Caronna, Elena Ruiz De La Torre, Messoud Ashina, Pablo Irimia, Antoinette MaassenVanDenBrink, Dimos D Mitsikostas, Christian Lampl, Raquel Gil-Gouveia, Faisal Mohammad Amin, Gisela M Terwindt, David Hurtado, Carmen Fairley, Peter J Goadsby","doi":"10.1177/03331024261471185","DOIUrl":"https://doi.org/10.1177/03331024261471185","url":null,"abstract":"<p><p>BackgroundAvailable instruments to quantify migraine-related disability, such as the Headache Impact Test (HIT-6) and Migraine Disability Assessment Test (MIDAS), have certain limitations (e.g., recall bias, overlooking interictal burden), and do not always facilitate patient-doctor communication. We developed a migraine scoring system, namely the European Migraine and Headache Alliance-Migraine Scoring System (EMHA-MSS) with the aim of improving patient communication with healthcare professionals.MethodsCross-sectional, descriptive, quantitative study conducted between June 2024 and March 2025. First, we used exhaustive diary registries from 319 Spanish-speaking patients for a pilot study (of whom <i>n</i> = 280 had complete HIT-6/MIDAS). Second, the EMHA-MSS was administered to a validation cohort of Spanish patients (<i>N</i> = 504). Third, we undertook cross-language analyses using a separate English-language dataset from English-speaking patients (<i>N</i> = 51). The pilot benchmarking analyses used an exploratory three-item version of the scale with different scoring, whereas the final psychometric analyses used the four-item EMHA-MSS.ResultsThe EMHA-MSS demonstrated unidimensional structure with excellent Confirmatory Factor Analysis fit (Comparative Fit Index = 1.000, Tucker-Lewis Index = 1.000, Root Mean Square Error of Approximation = 0.000, Standardized Root Mean Residual = 0.003). Acute treatment reliability was identified as the main factor driving reclassification between severity categories when comparing EMHA-MSS and HIT-6 or MIDAS (comparisons used an exploratory 3-item EMHA-MSS with different scoring in the pilot cohort). Our model provided an excellent fit, supported the expected factorial structure, and demonstrated that factor scores could be reliably calculated. The EMHA-MSS showed good to excellent test-retest reliability. Cross-language validity was demonstrated for the English version using configural and metric invariance, as well as partial scalar invariance.ConclusionThe EMHA-MSS highlighted the importance of treatment reliability, pain and attack intensity, and frequency in classifying patients with migraine and evaluating the severity of the disease. This novel scoring system could facilitate tailored management and monitoring of migraine over time, potentially improving alignment with patients' perceptions and enhancing the understanding between them and healthcare providers.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 9","pages":"3331024261471185"},"PeriodicalIF":5.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148879299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing the clinical profile of primary headache using explainable artificial intelligence.","authors":"Idris Demirsoy, Merve Hilal Ceren Akgör, Masahito Katsuki, Yasuhiko Matsumori, Derya Uludüz, Aynur Ozge","doi":"10.1177/03331024261479693","DOIUrl":"10.1177/03331024261479693","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Background/HypothesisDifferentiating primary from secondary headaches remains challenging due to overlapping symptoms and the subjective nature of pain assessment. Machine learning (ML) combined with explainable artificial intelligence (XAI) offers a promising approach for improving diagnostic accuracy while maintaining clinical interpretability. The study aimed to develop an interpretable ML model to differentiate primary from secondary headaches and to identify the relative diagnostic contributions of individual clinical features.MethodsThis cross-sectional study analyzed 1219 patients using routine clinical history variables, including 21 triggers, 15 associated symptoms, temporal patterns, pain intensity (visual analog scale [VAS]), and demographic factors. Data were obtained from the Global Migraine and Pain Society (GMPS) registry and the epikriz.com/headache platform, restricted to patients managed by specialist headache neurologists at two headache clinics in Türkiye. The binary classification outcome was clinically assigned headache label: primary versus secondary headache disorder (primary headache designated as the positive class). An eXtreme Gradient Boosting (XGBoost) classifier was developed with Random Over-Sampling Examples to address class imbalance, which was applied exclusively to the training partition. Model interpretability was achieved using SHapley Additive exPlanations (SHAP) and Local Interpretable Model-agnostic Explanations (LIME).ResultsThe model demonstrated excellent discrimination (AUC = 0.905), with sensitivity of 90.8%, specificity of 87.5%, precision of 99.7%, and an F1-score of 0.950. Associated symptom burden was the strongest predictor of primary headache classification (mean absolute SHAP = 1.075), driven principally by nausea, phonophobia, and photophobia. Trigger burden ranked second (mean absolute SHAP = 0.790), with stress, hunger, and odors most prevalent. Two laterality features independently discriminated headache type: strictly unilateral side-shifting (mean absolute SHAP = 0.545) and unilateral-to-bilateral transition (mean absolute SHAP = 0.481), both favoring primary classification. Higher diurnal pattern scores were associated with secondary headache disorders (mean absolute SHAP = 0.257). VAS contributed minimally (mean absolute SHAP = 0.101), suggesting that the syndromic profile outperforms pain severity as a diagnostic discriminator in this cohort.Conclusion/InterpretationIn this cohort, an ML model incorporating trigger profiles, associated symptoms, and temporal headache characteristics demonstrated good discrimination between clinically assigned primary and secondary headache labels. Associated symptom burden and trigger burden were more influential in model classification than pain intensity. This finding aligns with clinical practice, where headache diagnosis relies on symptom patterns and triggers rather than pain intensity alone. XAI frameworks may help make such classification m","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 8","pages":"3331024261479693"},"PeriodicalIF":5.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Migraine and headache in children and adolescents: A 2026 evidence-based factsheet.","authors":"Derya Uludüz, Ishaq Abu-Arafeh, Serena Laura Orr, Nazia Karsan, Vanda Faria, Nana Nino Tatishvili, Marco Lisicki, Toshiyuki Hikita, Hamit Genç, Aynur Özge","doi":"10.1177/03331024261463173","DOIUrl":"10.1177/03331024261463173","url":null,"abstract":"<p><p>BackgroundHeadache disorders, particularly migraine, are among the leading causes of disability worldwide, with onset frequently occurring during childhood and adolescence. Despite their high prevalence and substantial functional impact, paediatric headache disorders remain under-recognised within health systems and under-represented in global policy frameworks.MethodsThis factsheet was developed to provide a comprehensive, developmentally informed overview of the global burden of headache disorders in children and adolescents. It synthesises evidence from population-based studies, systematic reviews, clinical cohorts, and Global Burden of Disease (GBD) 2023 estimates. Key domains include epidemiology, disability burden, functional and psychosocial impacts, risk factors and triggers, diagnostic and treatment gaps, and current management strategies, with particular attention to disparities across sociodemographic groups.ResultsAccording to GBD 2023 point-prevalence estimates, headache disorders increase markedly across development, from 10.71% among children aged 5-9 years to 42.64% among adolescents aged 15-19 years. Corresponding migraine prevalence estimates increase from 2.79% to 18.08%. GBD 2023 data also indicate that migraine is among the leading causes of years lived with disability from early life onwards.Migraine in children and adolescents is associated with substantial impairment in school attendance, academic performance, social participation, and quality of life. It is also frequently accompanied by psychiatric and somatic comorbidities. Access to timely diagnosis and evidence-based treatment remains highly inequitable, particularly in low- and middle-income countries. Emerging evidence suggests that adolescence may represent a critical window for intervention, with the potential to reduce progression to chronic migraine and long-term disability.ConclusionsMigraine and other headache disorders in children and adolescents constitute a major global public health challenge. This factsheet provides a comprehensive, evidence-based summary of their burden and highlights urgent priorities for policy integration, advocacy, and research. Early, equitable, and developmentally tailored care is essential to reduce lifelong disability and improve global brain health outcomes.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 8","pages":"3331024261463173"},"PeriodicalIF":5.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased markers of heavy metal exposure and DNA methylation in cluster headache.","authors":"Joseph Lloyd, Katrin Wellfelt, Felicia Jennysdotter Olofsgård, Clémence Deborgies Sanches, Anna Steinberg, Anna Sundholm, Caroline Ran, Andrea Carmine Belin","doi":"10.1177/03331024261480707","DOIUrl":"10.1177/03331024261480707","url":null,"abstract":"<p><p>Background/HypothesisRates of tobacco usage are higher in individuals with cluster headache. Tobacco usage exposes the user to a large variety of toxic compounds, detrimental to health, including heavy metals. We hypothesise that exposure to heavy metals through tobacco usage will drive epigenetic alterations in individuals with cluster headache.To elucidate the extent of heavy metal exposure and global epigenetic alterations arising from tobacco products in relation to cluster headache we performed a case-control study, using DNA methylation, gene and protein expression analysis to evaluate markers for smoking, epigenetic modifications and heavy metal exposure.MethodsRNA was purified from collected blood samples from 16 cluster headache participants and 16 control participants, converted to cDNA, and RNA expression quantified via RT-qPCR. This was done by investigating genes relevant for nicotine exposure; nicotinic acetylcholine receptors (nAChRs), heavy metal exposure; metallothionein (MT) family, markers of liver and kidney damage (ALT, Alb and NGAL), epigenetic enzymes for DNA methylation (DNMTs) and demethylation (TETs), normalized to the housekeeping gene TBP. MT3 protein expression was quantified using an ELISA kit in cerebrospinal fluid from 13 cluster headache participants and 13 control participants. The methylation status of CpG-rich regions of long-interspersed nucleotide element-1 (LINE-1), in bisulfite converted DNA of 20 smoking individuals with cluster headache, 33 non-smoking individuals with cluster headache and 26 control participants, was quantified by pyrosequencing.ResultsAn increased RNA expression of nicotinic acetylcholine receptor subunits <i>CHRNA6</i> and <i>CHRNA7</i> was found in the cluster headache group compared to controls. Additionally, there were an increased RNA expression of MT1H and increased protein levels of MT3 along with a decreased RNA expression of DNMT1. A positive correlation was found between the RNA expression of <i>CHRNA7</i> and <i>MT1H</i> and a negative correlation was found between <i>CHRNA6</i> and <i>DNMT1</i>.ConclusionIndirect evidence indicates heavy metal exposure in relation to cluster headache as well as a tendency for alterations in global DNA methylation. This supports the hypothesis that heavy metal exposure from smoking contributes towards the pathophysiology of cluster headache.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 8","pages":"3331024261480707"},"PeriodicalIF":5.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of lumbar puncture in identifying secondary causes of visual snow syndrome: A case-control study.","authors":"Tim Mader, Antonia Klein, Elena Wenz, Adrian Scutelnic, Nedelina Slavova, Sophie De Beukelaer, Laura Weichsel, Michael Horn, Franz Riederer, Christoph J Schankin","doi":"10.1177/03331024261469080","DOIUrl":"10.1177/03331024261469080","url":null,"abstract":"<p><p>AimVisual Snow Syndrome (VSS) typically begins in early life with no significant diagnostic findings in the neurological and ophthalmological workups. Still, secondary forms of VSS have been reported. This study examines the diagnostic value of cerebrospinal fluid (CSF) analysis and the search for autoimmune encephalitis antibodies in patients with VSS.MethodsIn this retrospective case-control study, CSF samples from 36 VSS patients were analyzed and compared to a control group matched for age, sex, and migraine. In addition, serum and CSF antibodies associated with autoimmune encephalitis or paraneoplastic syndromes were analyzed in VSS patients. Cases with CSF abnormalities were further characterized.ResultsNo significant systematic differences in CSF cell count or protein levels were observed between VSS patients (n = 36) and controls (n = 31). CSF abnormalities in the VSS group included elevated cell counts (n = 4), elevated protein level (n = 1) and oligoclonal bands (n = 1). Autoantibodies associated with autoimmune encephalitis or paraneoplastic syndromes were not detected in either serum or CSF of VSS patients.ConclusionThis corresponds to grade 3b evidence (case-control study), suggesting that lumbar puncture and search for autoimmune encephalitis should not be routinely performed in patients presenting with typical VSS without red flags for additional comorbidities.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 8","pages":"3331024261469080"},"PeriodicalIF":5.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological considerations regarding smoking, psychological distress, and medication-overuse headache.","authors":"Nabira Tariq, Muhammad Awais Amir","doi":"10.1177/03331024261471862","DOIUrl":"https://doi.org/10.1177/03331024261471862","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 8","pages":"3331024261471862"},"PeriodicalIF":5.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148648432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extension.","authors":"Shengyuan Yu, Hui Su, Hebo Wang, Meiyun Zhang, Steve Barash, Glenn Chen, Gloria Yiu, Juline Bryson, Yoel Kessler, Yael Carmeli Schwartz, Zipi Roth-Ben Arie, Michal Benedek-Segal, Xiaoping Ning","doi":"10.1177/03331024261462833","DOIUrl":"10.1177/03331024261462833","url":null,"abstract":"<p><p>AimFremanezumab is approved for migraine prevention in Europe, the United States (US), Japan, South Korea, and several other countries; however, there are no data available on fremanezumab as a migraine preventive treatment in a Chinese population. This study evaluated the efficacy and safety of fremanezumab in Chinese adults with migraine.MethodsThis randomized, multicenter, Phase 3 trial consisted of a 4-week screening period, a 12-week double-blind period (DBP), and a 12-week open-label extension (OLE). Chinese adults with episodic and chronic migraine were randomized 1:1:2 to receive fremanezumab monthly (225 mg), fremanezumab quarterly (675 mg), or matched monthly placebo during the DBP. During the OLE, all participants received fremanezumab monthly (225 mg). The primary endpoint was mean change from baseline in monthly migraine days (MMD) during the DBP. Secondary endpoints included mean change from baseline in migraine days during the first 4 weeks of treatment and in monthly number of days with acute headache medication use during the DBP. Similar endpoints were assessed during the OLE. Safety assessments included, but were not limited to, adverse event (AE) reporting.ResultsIn total, 365/454 screened participants were randomized to fremanezumab (n = 182 [monthly, n = 91; quarterly, n = 91]) or placebo (n = 183). Significantly greater changes from baseline in MMD were observed with fremanezumab versus placebo during the DBP (-4.6 vs -2.8; <i>p</i> < 0.0001) and in mean migraine days during the first 4 weeks of treatment (-4.5 vs -2.2; <i>p</i> < 0.0001). The mean change from baseline in days of acute headache medication use during the DBP was -3.0 with fremanezumab and -1.1 for placebo (<i>p</i> < 0.0001). During the OLE, the mean change from baseline in MMD was -6.8 and -7.2 for those assigned to fremanezumab and placebo, respectively, during the DBP. The percentage of participants with any AE was similar between fremanezumab and placebo groups during the DBP (47% vs 43%); serious AEs were infrequent (fremanezumab, 1%; placebo, <1%). Similar trends in AEs were observed during the OLE.ConclusionIn this study, fremanezumab demonstrated significant improvements over placebo with respect to reductions in MMD and days with acute headache medication use, with these reductions being maintained over the OLE. Fremanezumab demonstrated a favorable safety profile, with no safety signals. These results are comparable to pivotal adult trials in Europe and the US, supporting the use of fremanezumab in Chinese adults living with migraine.Clinical trial pre-registrationClinicalTrials.gov identifier: NCT05458011; submitted: 11 July 2022; first participant enrolled: 30 September 2022; available at: https://clinicaltrials.gov/study/NCT05458011; first submitted: 11 July 2022).</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 8","pages":"3331024261462833"},"PeriodicalIF":5.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline severity is not treatment timing in acute rimegepant treatment for vestibular migraine.","authors":"Yuhan Liang, Haoyang Hu","doi":"10.1177/03331024261474832","DOIUrl":"https://doi.org/10.1177/03331024261474832","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 8","pages":"3331024261474832"},"PeriodicalIF":5.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}